āshibio, Inc

We‘re excited to announce the dosing of the first patient in the ANDECAL study for the treatment of fibrodysplasia ossificans progressiva (FOP). FOP is a rare genetic disorder that typically starts in early childhood, causes painful flare-ups and progressive heterotopic ossification, and leads to severe debilitation and shortened life span.? ? This is our first clinical trial in a set of indications characterized by heterotopic ossification (HO), a pathological condition that causes abnormal bone formation in soft tissues such as muscles, tendons, and ligaments. We are starting development in FOP and plan to expand to other forms of non-genetic HO in the near future.? ? The milestone further advances our commitment to delivering innovative therapeutics to impact bone and connective tissue disorders with high unmet need.? ? Read more here: https://bit.ly/40velc8 ? #raredisease #biopharma #lifesciences?

#HappyHolidays from our team. The past year has been one of exciting advancements for our clinical program for FOP, and our pipeline of novel therapies for bone and connective tissue disorders. As we pause to reflect, we are grateful for the support of patient communities and other stakeholders and look forward to continued progress in 2025!

We are excited to unveil our updated website! As we continue to make strides in the clinic, our refreshed design demonstrates our company's growth and commitment to advancing our pipeline for bone and connective tissue disorders, beginning with our fibrodysplasia ossificans progressiva (FOP) program. Check out our new look and additional information on our company and lead program here: https://ashibio.com/

We were delighted to attend the International FOP Association Family Gathering in Denver where our CMO, Dr. Deborah Wenkert participated in a panel on #ClinicalTrials in FOP. This #Thanksgiving, we are thankful for the dedication of our team as we continue to advance our clinical program developing a potential treatment for fibrodysplasia ossificans progressiva (FOP). We are grateful for the opportunity to work with the FOP community, physicians, and scientists as we collaborate to improve the lives of individuals living with FOP. #curefop #raredisease #biotech #lifesciences?

We were delighted to attend the International FOP Association Family Gathering in Denver where our CMO, Dr. Deborah Wenkert participated in a panel on #ClinicalTrials in FOP. This #Thanksgiving, we are thankful for the dedication of our team as we continue to advance our clinical program developing a potential treatment for fibrodysplasia ossificans progressiva (FOP). We are grateful for the opportunity to work with the FOP community, physicians, and scientists as we collaborate to improve the lives of individuals living with FOP. #curefop #raredisease #biotech #lifesciences?

Delighted to welcome Dipal Doshi to our Board and looking forward to working with him as we write the next chapter of ashibio!

We are incredibly excited to welcome Dipal Doshi, CEO of Entrada Therapeutics, to our Board of Directors. Dipal has a long record of accomplishment setting strategy and driving operational and commercial growth for #biopharma companies, and his experience will be invaluable in the next phase of āshibio. We look forward to his involvement as we develop novel therapies for bone and connective tissue disorders, including our lead asset for potential treatment of fibrodysplasia ossificans progressiva (FOP). Read the announcement here: https://bit.ly/3XrQOY8 #raredisease #biotech #lifesciences

It has been an exciting start to the summer for our team, as we exited stealth mode and announced $40M in seed and Series A financing on June 20. Last month our leadership team of CEO Pankaj Bhargava, CSO ?Victoria Smith, and CMO Deborah Wenkert attended the FOP Drug Development Forum and the International Conference on Children’s Bone Health (ICCBH). During those events we had the chance to share details of our upcoming clinical trial of andecaliximab for the treatment of fibrodysplasia ossificans progressiva (FOP). It was a pleasure to connect with the FOP community, hear their stories, and share our goals. In case you missed our news, you can see it here: ?https://bit.ly/3Rw9TG7 International FOP Association #raredisease #biotech #lifesciences #biopharma